Y-mAbs Therapeutics Reports Q2 Earnings and Acquisition

Y-Mabs Therapeutics ( (YMAB) ) has released its Q2 earnings. Here is a breakdown of the information Y-Mabs Therapeutics presented to its investors.

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based therapeutic products for cancer treatment.

In its latest earnings report, Y-mAbs Therapeutics announced total revenues of $19.5 million for the second quarter of 2025, surpassing its guidance range. Additionally, the company revealed a significant corporate development, with SERB Pharmaceuticals set to acquire Y-mAbs in a $412 million transaction expected to close by the fourth quarter of 2025.

The financial results for the quarter showed a decline in total revenues by 14% compared to the same period in 2024, primarily due to decreased sales of its DANYELZA product both in the U.S. and internationally. Despite this, the company managed to reduce its net loss to $3.2 million, a notable improvement from the $9.2 million loss in the previous year, aided by foreign currency gains and reduced operating expenses.

The acquisition by SERB Pharmaceuticals, which offers a 105% premium on Y-mAbs’ share price, marks a strategic move that could potentially enhance Y-mAbs’ market position and financial stability. The transaction’s completion is contingent upon customary conditions and regulatory approvals.

Looking ahead, Y-mAbs’ management remains focused on its strategic priorities and operational efficiency, with the anticipated acquisition by SERB Pharmaceuticals poised to provide new opportunities for growth and innovation in the biopharmaceutical sector.